Background: A potential link between increase in total cholesterol and triglycerides and clinical improvement has been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug related effects on lipid biosynthesis. We examined whether changes in serum lipids are associated with alleviation of psychosis symptoms after one year of antipsychotic drug treatment in a cohort of first-episode psychosis (FEP) patients. Methods: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)), body mass index (BMI) and clinical state were obtained at baseline and after 12 months. The Positive and Negative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed to examine the relationship between serum lipids and psychotic symptoms while controlling for potential confounders including BMI. Results: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS negative subscores (B = −0.48, p = 0.03). This relationship was not affected by concurrent change in BMI (adjusted HDL: B = −0.54, p = 0.02). No significant associations were found between serum lipids, BMI and PANSS positive subscores. Conclusion: We found that an increase in HDL level during antipsychotic treatment is associated with improvement in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction between lipid pathways and psychosis.
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Introduction
Metabolic disturbances such as obesity and dyslipidemia are common in schizophrenia (Allison et al., 1999; Mitchell et al., 2013; Vancampfort et al., 2013) . These metabolic abnormalities may be caused by environmental factors, but can also be intrinsic to the illness itself (Mitchell et al., 2013; Vancampfort et al., 2013) . Indeed, dyslipidemia has been observed in antipsychotic-naive and in first-episode psychosis (FEP) patients (Chen et al., 2013; De Hert et al., 2006; Enez Darcin et al., 2014; Fleischhacker et al., 2013; Kaddurah-Daouk et al., 2012; Misiak et al., 2016; Saari et al., 2004; Thakore, 2004; Verma et al., 2009; Wu et al., 2013; Zhai et al., 2017) . In line with these findings, there is also evidence of overlapping genetic markers between disturbed lipid metabolism and schizophrenia (Andreassen et al., 2013 
